Boothbay Fund Management LLC Increases Stake in Indivior PLC (NASDAQ:INDV)

Boothbay Fund Management LLC lifted its holdings in Indivior PLC (NASDAQ:INDV - Free Report) by 65.5% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 458,874 shares of the company's stock after purchasing an additional 181,637 shares during the period. Boothbay Fund Management LLC owned about 0.33% of Indivior worth $5,879,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Claret Asset Management Corp purchased a new stake in shares of Indivior in the 4th quarter worth $9,304,000. CenterBook Partners LP raised its stake in shares of Indivior by 105.5% in the fourth quarter. CenterBook Partners LP now owns 1,147,841 shares of the company's stock worth $14,268,000 after buying an additional 589,158 shares during the period. Marshall Wace LLP lifted its position in shares of Indivior by 659.7% during the 4th quarter. Marshall Wace LLP now owns 506,782 shares of the company's stock valued at $6,299,000 after buying an additional 440,072 shares in the last quarter. SIH Partners LLLP bought a new position in shares of Indivior during the 4th quarter valued at approximately $2,698,000. Finally, Kazazian Asset Management LLC purchased a new stake in Indivior in the 4th quarter worth approximately $1,706,000. Hedge funds and other institutional investors own 60.33% of the company's stock.

Indivior Stock Up 0.3 %

Indivior stock traded up $0.04 during midday trading on Thursday, reaching $11.55. 597,284 shares of the stock traded hands, compared to its average volume of 975,438. Indivior PLC has a 12 month low of $7.33 and a 12 month high of $18.59. The stock's fifty day moving average is $9.61 and its 200-day moving average is $10.38. The stock has a market cap of $1.59 billion, a P/E ratio of -33.00 and a beta of 0.93.

Indivior (NASDAQ:INDV - Get Free Report) last announced its quarterly earnings results on Thursday, April 24th. The company reported $0.41 earnings per share for the quarter, topping the consensus estimate of $0.22 by $0.19. Indivior had a negative net margin of 3.96% and a negative return on equity of 241.73%. The company had revenue of $266.00 million for the quarter, compared to analysts' expectations of $240.13 million. On average, equities analysts predict that Indivior PLC will post 1.22 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on INDV shares. Rodman & Renshaw assumed coverage on shares of Indivior in a research report on Tuesday, January 28th. They issued a "buy" rating and a $16.00 price target for the company. RODMAN&RENSHAW upgraded Indivior to a "strong-buy" rating in a research note on Tuesday, January 28th. Finally, Piper Sandler lowered their price objective on Indivior from $16.00 to $13.00 and set an "overweight" rating on the stock in a research report on Thursday, March 6th.

Indivior Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.